Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 9,601–9,700 of 15,747
Accelerated waning of the humoral response to SARS-CoV-2 vaccines in obesityPreprint
van der Klaauw, A. A., Horner, E. C., Pereyra-Gerber, P., Agrawal, U., Foster, W. S., Spencer, S., Vergese, B., Smith, M., Henning, E., Ramsay, I. D., et al. (2022) · medRxiv · doi:10.1101/2022.06.09.22276196 · Cited by 5
Menstrual Irregularities Post-COVID-19 Infection/Vaccination in Indian Population
Moolamalla, S., Bakshi, K., & Vijayasree, M. (2023) · Journal of South Asian Federation of Obstetrics and Gynaecology · doi:10.5005/jp-journals-10006-2163 · Cited by 5
Virtual autopsy in SARS-CoV-2 breakthrough infection: a case report
Filograna, L., Manenti, G., Grassi, S., Zedda, M., Cazzato, F., Ryan, C. P., Arena, V., Pascali, V. L., Colosimo, C., Floris, R., et al. (2022) · Forensic Imaging · doi:10.1016/j.fri.2022.200520 · Cited by 5
RNA technology and nanocarriers empowering in vivo chimeric antigen receptor therapy
Cai, J., Chen, S., Liu, Z., Li, H., Wang, P., Yang, F., Li, Y., Chen, K., Sun, M., & Qiu, M. (2024) · Immunology · doi:10.1111/imm.13861 · Cited by 7
“…significant progress in RNA optimisation and delivery tools, it took nearly 60 years for mRNA to gain its first approval, which came in 2020 when two mRNA COVID-19 vaccines (Moderna ’ s mRNA-1273 and Pfizer ’ s BNT162b2) were granted emergency use authorization in the United States [34, 35, 57].”
InfluentialPates, K. M., Periselneris, J. N., & Brown, J. (2023) · Medicine · doi:10.1016/j.mpmed.2023.08.003 · Cited by 5
Orthoflavivirus zikaense (Zika) vaccines: What are we waiting for?
Cagigi, A., Tinnirello, R., Iannolo, G., & Douradinha, B. G. (2024) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2024.107367 · Cited by 5
Niazi, S. K., & Ómarsdóttir, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179240 · Cited by 5
Durability of COVID-19 humoral immunity post infection and different SARS-COV-2 vaccines
Alroqi, F. J., Barhoumi, T., Masuadi, E., Nogoud, M., Aljedaie, M., Abu-Jaffal, A. S., Bokhamseen, M., Saud, M., Hakami, M., Arabi, Y. M., et al. (2024) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2024.02.016 · Cited by 5
Cagna, D. R., Donovan, T. E., McKee, J. R., Eichmiller, F. C., Metz, J. E., Albouy, J.-P., Marzola, R., Murphy, K. G., & Troeltzsch, M. (2021) · Journal of Prosthetic Dentistry · doi:10.1016/j.prosdent.2021.06.014 · Cited by 7
Peripheral facial palsy post SARS-CoV-2 vaccine: A regional pharmacovigilance cases series
Chamboux, M., Simon, C., Beau-Salinas, F., Maurier, A., Agier, M., Thillard, E. M., Largeau, B., & Jonville‐Béra, A. ‐. (2023) · Therapies · doi:10.1016/j.therap.2023.02.005 · Cited by 6
“[1] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.”
McClymont, E., Atkinson, A., Albert, A., Av‐Gay, G., Andrade, J., Barrett, J. F. R., Bogler, T., Boucoiran, I., Castillo, E., D'Souza, R. D., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.10.032 · Cited by 5
Łukaszuk, K., Wocławek-Potocka, I., Jakiel, G., Malinowska, P., Wdowiak, A., Rozanska, K., & Rąbalski, Ł. (2021) · Vaccines · doi:10.3390/vaccines9101151 · Cited by 6
“AIIRD patients undergoing immunosuppressive therapy were not included in the COVID-19 vaccine clinical trials [12,13], so it was not known what their response to the vaccination would look like.”
BackgroundDeichmann, J., Barda, N., Canetti, M., Peretz, Y., Weiss-Ottolenghi, Y., Lustig, Y., Regev‐Yochay, G., & Lipsitch, M. (2025) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1013192 · Cited by 6
Central nervous system manifestations following vaccination against COVID-19
Khatami, S. S., Revheim, M.-E. R., Høilund‐Carlsen, P. F., Alavi, A. A., Shirkouhi, S. G., & Andalib, S. (2024) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2024.100788 · Cited by 7
Distorted Human Decision-Making as a Critical Aspect of Pandemic Planning and Preparedness.
Poland, C. M., Ratishvili, T., & Poland, G. A. (2022) · PubMed Central · Cited by 8
Design and in silico analysis of mRNA vaccine construct against Salmonella
Imdad, M. J., Khan, M. N., Alam, H. S., Khan, A. B., Mirani, Z. A., Khan, A. U., & Ahmed, F. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2119280 · Cited by 5
“Both have undergone successful clinical trials and have demonstrated over 90% efficacy (Baden et al., 2020; Polack et al., 2020).”
BackgroundManagement of inflammatory bowel disease during the COVID-19 pandemic
Hisamatsu, T. (2021) · Immunological Medicine · doi:10.1080/25785826.2021.1978205 · Cited by 5
Brook, B., Fatou, B., Checkervarty, A. K., Barman, S., Sweitzer, C., Bosco, A.-N., Sherman, A. C., Baden, L. R., Morrocchi, E., Sánchez‐Schmitz, G., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2395118/v1 · Cited by 6
Tani, C., Cardelli, C., Depascale, R., Gamba, A., Iaccarino, L., Doria, A., Bandeira, M., Dinis, S. P., Romão, V. C., Gotelli, E., et al. (2023) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2023.100221 · Cited by 8
Biopharmaceuticals for prevention of COVID-19: A scoping review
Farjami, A., Montazersaheb, S., Soofiyani, S. R., Akbarzadehlaleh, P., & Salatin, S. (2022) · Asian Pacific Journal of Tropical Medicine · doi:10.4103/1995-7645.348158 · Cited by 6
Autoimmune and auto-inflammatory adverse events after COVID-19 vaccination in the United States
Kim, S., Rhee, T. G., & Shim, S. R. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109882 · Cited by 5
Immunomics in one health: understanding the human, animal, and environmental aspects of COVID-19
Gao, J., Zhang, C., Wheelock, Å. M., Xin, S., Cai, H., Xu, L., & Wang, X.-J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1450380 · Cited by 7
Güven, E. (2021) · Gene Reports · doi:10.1016/j.genrep.2021.101169 · Cited by 6
Ordered mesoporous silicas for potential applications in solid vaccine formulations
Miranda, M. C. R., Nunes, C. M., Santos, L. F., da Silva, L. B., de Jesus, V. R., Andréo‐Filho, N., Pedro, J. A. F., Lopes, J. L. D. S., Oliveira, C. L. P., Fantini, M. C. D. A., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.12.032 · Cited by 5
Yu, X., He, Q., & Kong, Q. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1387623 · Cited by 7
“For example, the Pfizer-BioNTech and Moderna COVID-19 vaccines utilize LNPs to encapsulate and deliver mRNA encoding the spike protein of SARS-CoV-2, eliciting an immune response against the virus (Polack et al., 2020; Baden et al., 2021).”
BackgroundThe RNA delivery dilemma—lipid versus polymer nanoparticle platforms
Martins, C., Mitchell, M. J., Peer, D., Perrie, Y., Siegwart, D. J., Alonso, M. J., & Aparicio-Blanco, J. (2026) · Drug Delivery and Translational Research · doi:10.1007/s13346-026-02044-6 · Cited by 14
“The field accelerated dramatically during the COVID-19 pandemic, with the global deployment of mRNA vaccines from Moderna (Spikevax) and BioNTech/Pfizer (Comir-naty) in 2020–2021 [25, 26].”
Lü, J., Tan, S., Gu, H., Liu, K., Huang, W., Yu, Z., Lu, G., Wu, Z., Gao, X., Zhao, J., et al. (2024) · Emerging Microbes & Infections · doi:10.1080/22221751.2024.2321994 · Cited by 6
“…comprises two mRNA sequences (RQ3013 and RQ3019) encoding chimeric S proteins incorporating key mutation sites found in Alpha, Beta, and Omicron BA.2/ In developing vaccines against SARS-CoV-2, concerns about VAERD arose, although it has not been reported in humans receiving current vaccines [1,2].”
BackgroundSARS-CoV-2 Spike Protein-Expressing Enterococcus for Oral Vaccination: Immunogenicity and Protection
Suvorov, A. N., Loginova, S. Y., Leontieva, G., Gupalova, T. V., Desheva, Y. A., Korzhevsky, D. E., Kramskaya, T. A., Bormotova, E., Koroleva, I. V., Kopteva, O. S., et al. (2023) · Vaccines · doi:10.3390/vaccines11111714 · Cited by 5
Real-World COVID-19 Vaccine Protection Rates against Infection in the Delta and Omicron Eras
Zhu, Y., Gu, J., Qiu, Y., & Chen, S. X. (2023) · Research · doi:10.34133/research.0099 · Cited by 9
“Clinical trials or observa‑ tional studies have been made to evaluate the effects of a vaccine or an arrangement of mixed vaccines [3–9].”
InfluentialDeterministic and Stochastic Dynamics of COVID-19: The Case Study of Italy and Spain
Srivastav, A. K., Stollenwerk, N., & Aguiar, M. (2022) · Computational and Mathematical Methods · doi:10.1155/2022/5780719 · Cited by 5
Horndler, L., Delgado, P., Romero-Pinedo, S., et al. (2021) · medRxiv · doi:10.1101/2021.08.12.21261952 · Cited by 5
Infection prevention and vaccination in the rheumatic diseases
Morel, J. (2023) · Joint Bone Spine · doi:10.1016/j.jbspin.2023.105568 · Cited by 5
Hwang, S., Kang, S. W., Choi, J., Park, K., Lim, D. H., Shin, J., Kang, D., Cho, J., & Kim, S. J. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.08.015 · Cited by 6
Improved Survival of Lymphoma Patients with COVID-19 in the Modern Treatment and Vaccination Era
Pia, A. D., Zhao, C., Jandir, P., Gupta, A., Batistick, M., Kim, G. Y., Xia, Y., Ahn, J., Magarelli, G., Lukasik, B., et al. (2022) · Cancers · doi:10.3390/cancers14174252 · Cited by 6
“1% (Moderna, mRNA-1273 vaccine) efficacy in preventing severe COVID-19 infection in the general population [6,7].”
BackgroundHu, C., Dai, Y., Zhou, H., Zhang, J., Xie, D., Xu, R., Yang, M., & Zhang, R. (2022) · Hereditas · doi:10.1186/s41065-022-00258-5 · Cited by 5
“The spike (S) protein of coronaviruses plays an important role in viral attacking cells [46, 47].”
BackgroundImproved mRNA-based RSV vaccine with PreF forming enveloped virus-like particles
Chai, P., Shi, Y., Li, X., Yang, M., Liu, X., Liu, M., Yu, J., Yin, X., Li, D., Li, K., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01205-x · Cited by 8
Current landscape and challenges in adjuvant and antigen delivery systems for vaccine
Fu, X. (2025) · Vaccine X · doi:10.1016/j.jvacx.2025.100735 · Cited by 11
Modeling the systemic risks of COVID-19 on the wildland firefighting workforce
Belval, E. J., Bayham, J., Thompson, M. P., Dilliott, J., & Buchwald, A. G. (2022) · Scientific Reports · doi:10.1038/s41598-022-12253-x · Cited by 6
Abdulah, D. M., & Mirza, A. M. S. (2022) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2022.2194 · Cited by 4
Protection against reinfection with SARS-CoV-2 omicron BA.2.75 * sublineagePreprint
Chemaitelly, H. S., Tang, P., Coyle, P. V., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Hasan, M. R., Ayoub, H. H., Altarawneh, H. N., Kanaani, Z. A., et al. (2022) · medRxiv · doi:10.1101/2022.10.29.22281606 · Cited by 5
The immunopathogenesis of SARS ‐CoV‐2 infection in children: diagnostics, treatment and prevention
Patel, H., McArdle, A. J., Seaby, E. G., Levin, M., & Whittaker, E. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1405 · Cited by 5
Zhang, J. Z., Yeh, H.-W., Walls, A., Wicky, B., Sprouse, K., VanBlargan, L. A., Treger, R. S., Quijano-Rubio, A., Pham, M. N., Kraft, J. C., et al. (2021) · bioRxiv · doi:10.1101/2021.06.22.449355 · Cited by 2
Lin, Z.-Q., Wu, J., Huang, R., Xie, F., Li, J., Zheng, K., & Zhang, D. (2022) · Vaccines · doi:10.3390/vaccines10040622 · Cited by 4
“For example, the efficacy of BNT162b2 against COVID-19 waned from 95% between 7 days and 2 months to 84% between 4 and 6 months after the second dose [2,3].”
BackgroundCardiovascular and Hematologic Complications of COVID-19 Vaccines
Herblum, J., & Frishman, W. H. (2022) · Cardiology in Review · doi:10.1097/crd.0000000000000457 · Cited by 4
Ganesan, S., Acosta, H., Brigolin, C., Orange, K., Trabbic, K. R., Chen, C., Lien, C.-E., Lin, Y., Lin, M., Chuang, Y.-S., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272594 · Cited by 6
“The BNT162b2 and mRNA-1273 vaccines reported a vaccine efficacy of ~95% and ~94%, respectively, after the administration of two doses [10,11].”
BackgroundKameyama, K., Nakae, H., & Irie, Y. (2022) · Personalized Medicine Universe · doi:10.46459/pmu.2021006 · Cited by 4
Sex differences in response to COVID-19 mRNA vaccines in Italian population
Ferroni, E., Mateo‐Urdiales, A., Bietta, C., Cesaroni, G., Anticoli, S., Maggio, E. D., Ancona, A., Petrone, D., Cannone, A., Sacco, C., et al. (2024) · Epidemiology and Infection · doi:10.1017/s0950268824001079 · Cited by 6
“…the inoculation of the vaccine to its immunological effect, based on the results of the trials that conducted to the authorization of mRNA vaccines [14], thus participants were classified as unvaccinated for the first 14 days post first dose and as incompletely vaccinated for the first 14 days…”
Kaarow, M., Graser, L., Knorr, E., Windfelder, A. G., Geisler, P., Steiniger, F., Oberpaul, M., Vilcinskas, A., & Hellmann, C. (2026) · Frontiers in Insect Science · doi:10.3389/finsc.2026.1770055 · Cited by 7
Structure and design of Langya virus glycoprotein antigens
Wang, Z., McCallum, M., Yan, L., Sharkey, W., Park, Y.-J., Dang, H. V., Amaya, M., Person, A., Broder, C. C., & Veesler, D. (2023) · doi:10.1101/2023.08.20.554025 · Cited by 32
“Prefusion-stabilization (2P) of coronavirus spike glycoproteins also led to the groundbreaking development of COVID-19 vaccines in a record time in 2020 49,69–71 .”
Ogawa, T., Yamada, T., Matsumoto, Y., Minami, K., Kawanishi, F., Nakano, T., & Ukimura, A. (2022) · Journal of International Medical Research · doi:10.1177/03000605221127518 · Cited by 4
“This result is consistent with those of previous studies examining AEs in Japanese participants older than 18 years.(13,14) We did not evaluate the severity of AEs other than fever; therefore, we could not evaluate the CTCAE grade for the severity of local reactions.”
ResultTalotta, R. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.07.007 · Cited by 5
Luthria, G., Baratto, L., Adams, L. C., Morakote, W., & Daldrup-Link, H. E. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.266271 · Cited by 4
Reimann, P., Petzer, V., Mündlein, A., Hartmann, B. R., Severgnini, L., Winkler, A., Lang, T., Huynh, M., Gasser, K., Rüger, J., et al. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05671-6 · Cited by 4
“Occurrence of adverse events after administration of tixagevimab/cilgavimab was documented using the stand-ardised safety questionnaire used by previous studies [23].”
España, P. P., Bilbao‐González, A., Larrea, N., Castillo-Sintes, I., García‐Gutiérrez, S., Portuondo, J., Villanueva, A., Uranga, A., Legarreta, M. J., Gascón, M., et al. (2023) · Aging Clinical and Experimental Research · doi:10.1007/s40520-023-02446-3 · Cited by 6
“However, this group was not included in COVID-19 vaccine clinical trials [2, 3] and only limited data are available on the effectiveness of vaccines among NHRs.”
BackgroundPyrazolidinone-based peptidomimetic SARS-CoV-2 Mpro inhibitors
Jelisejevs, D., Bula, A. L., & Kinena, L. (2023) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2023.129530 · Cited by 4
Parálisis de Bell tras vacunación COVID-19: a propósito de un caso
Caro, G. G. D. T., Díaz, S. G., Alé, M. P., & Martínez‐Gimeno, M. L. (2021) · Neurología · doi:10.1016/j.nrl.2021.04.004 · Cited by 7
James, N., & Menzies, M. (2023) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2023.114139 · Cited by 5
Why do people consent to receiving SARS-CoV2 vaccinations? A Representative Survey in GermanyPreprint
Walach, H., Ofner, M., Ruof, V., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1216502/v1 · Cited by 4
Kang, M. W., Kim, Y., Lee, I., Park, H., Park, J. Y., An, J. N., Yoo, K. D., Kim, Y. C., Park, N.-Y., Kho, Y., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-19787-0 · Cited by 5
Eisenmann, M., Rauschenberger, V., Knies, K., et al. (2022) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2021.234 · Cited by 4
Magalis, B. R., Mavian, C. N., Tagliamonte, M. S., Rich, S. N., Cash, M. N., Riva, A., Loeb, J. C., Norris, M. H., Amador, D. M., Zhang, Y., et al. (2021) · medRxiv · doi:10.1101/2021.05.19.21257237 · Cited by 6
Immune Response to SARS-CoV-2 Vaccine among Heart Transplant Recipients: A Systematic Review
Shoar, S., Prada-Ruiz, A. C., Patarroyo‐Aponte, G., Chaudhary, A., & Asadi, M. S. (2022) · Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine · doi:10.1177/11795484221105327 · Cited by 4
Amellal, H., Assaid, N., Akarid, K., Maaroufi, A., Ezzikouri, S., & Sarih, M. (2023) · Vaccine X · doi:10.1016/j.jvacx.2023.100288 · Cited by 5
“Several clinical trials have demonstrated the effectiveness of these vaccines [3].”
BackgroundScientific effort in combating COVID ‐19 in obstetrics and gynecology
Martinez-Portilla, R. J., Gil, M. M., & Poon, L. C. (2021) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.23584 · Cited by 4
Islam, Z., Yamamoto, S., Mizoue, T., Konishi, M., & Ohmagari, N. (2024) · Journal of Epidemiology · doi:10.2188/jea.je20230231 · Cited by 4
Grunau, B. E., Golding, L., Prusinkiewicz, M. A., Asamoah-Boaheng, M., Armour, R., Marquez, A. C., Jassem, A. N., Barakauskas, V., O’Brien, S. F., Drews, S. J., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02702-21 · Cited by 4
“Clinical trials have found the BNT162b2 and mRNA-1273 vaccines to be highly efficacious against short-term severe COVID-19 (1, 2).”
BackgroundKnudsen, M. L., Nielsen, S. D., & Heftdal, L. D. (2024) · Apmis · doi:10.1111/apm.13379 · Cited by 4
(2020) · Mediterranean Journal of Rheumatology · doi:10.31138/mjr.31.4.430 · Cited by 4
Research progress and prospect of vaccines for thecoronavirus disease 2019 (COVID-19)
Huan, Y., & Bi, Y. (2021) · Scientia Sinica Vitae · doi:10.1360/ssv-2021-0082 · Cited by 3
Assessing the dynamics and impact of COVID-19 vaccination on disease spread: A data-driven approach
Waseel, F., Streftaris, G., Rudrusamy, B., & Dass, S. C. (2024) · Infectious Disease Modelling · doi:10.1016/j.idm.2024.02.010 · Cited by 6
“Don’t Look Up” Your Science—Herd Immunity or Herd Mentality?
Igyártó, B. Z. (2022) · Microorganisms · doi:10.3390/microorganisms10071463 · Cited by 5
“A case was defined as an individual who experienced symptoms and had a positive test for SARS-CoV-2 infection [39].”
BackgroundSteinbeis, F., Thibeault, C., Steinbrecher, S., et al. (2023) · Infection · doi:10.1007/s15010-023-02057-0 · Cited by 4
Quantifying the potential dominance of immune-evading SARS-CoV-2 variants in the United StatesPreprint
Sah, P., VILCHES, T. N., Shoukat, A., Fitzpatrick, M. C., Pandey, A., Singer, B. H., Moghadas, S. M., & Galvani, A. P. (2021) · medRxiv · doi:10.1101/2021.05.10.21256996 · Cited by 5
Vaccine-induced immune thrombotic thrombocytopenia and patients with cancer
Connors, J. M., & Iba, T. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.02.009 · Cited by 21
Keane, A. E., Tippett, A., Taylor, E. G., Reese, O., Moscote‐Salazar, L. R., Castro, K. D., Choi, C., Ciric, C. R., Taylor, M., Mitchell, A., et al. (2024) · Vaccines · doi:10.3390/vaccines12060657 · Cited by 4
“In the phase 3 randomized controlled pivotal trial, vaccination with the BNT162b2 mRNA vaccine conferred 95% efficacy in the prevention of ancestral SARS-CoV-2 infections (e.g., Wa-1, D614G strains) in adults [5].”
BackgroundAbraham, B., Saeed, H., & Pasha, S. A. A. (2022) · Qatar medical journal · doi:10.5339/qmj.2022.40 · Cited by 4
“Sporadic vaccine-related adverse events are pertinent to the treating physician but do not depreciate the colossal benefit of vaccination and the wellvalidated safety profile of the Pfizer-BioNTech BNT16B2b2 mRNA vaccine.(1,2)”
Background(2021) · doi:10.21203/rs.3.rs-244176/v1 · Cited by 192
Randomised trials of COVID-19 vaccines in Africa – charting the path forward
Wiysonge, C. S., Ndwandwe, D. E., Mathebula, L., Goga, A. E., & Gray, G. (2022) · South African Journal of Science · doi:10.17159/sajs.2022/13224 · Cited by 5
Stefanizzi, P., Larocca, A. M. V., Martinelli, A., Soldano, S., Dell’Aera, M., Migliore, G., Germinario, C. A., Vimercati, L., Tafuri, S., & Bianchi, F. P. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.02.002 · Cited by 4
Saito, S., Kutsuna, S., Imamura, A., Hase, R., Oda, R., Terada-Hirashima, J., Shimizu, Y., Uemura, Y., Takamatsu, Y., Yasuhara, A., et al. (2023) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2023.05.012 · Cited by 4
“Furthermore, several vaccines, such as BNT162b2, are being used to prevent the onset and severity of COVID-19 [6].”
Efficacy and safety of a novel multivalent mRNA vaccine against SARS-CoV-2 in experimental animals
Min, S. E., Gu, E.-Y., Jang, M. S., Lee, Y.-J., Han, J., Lee, W. G., Jeong, S. I., Song, J. Y., Lee, I., Kwon, H., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-07661-8 · Cited by 5
Juxtaposition on Discrete Covid-19 Vaccines: For Rudimentary and Pivotal Cognizance
Chatki, P. K., & Tabassum, S. (2021) · International Journal of Advancement in Life Sciences Research · doi:10.31632/ijalsr.2021.v04i04.001 · Cited by 5
New onset of acute uveitis following COVID-19 vaccination
Sim, H., & Hwang, J. (2022) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-022-05798-0 · Cited by 6
Immunization: Unveiling the Power of Vaccines in Shaping Global Health
Hassan, S., Nazeer, I. M., & Raheem, A. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1003704 · Cited by 6
Modelling the population-level protection conferred by COVID-19 vaccination
Padmanabhan, P., Desikan, R., & Dixit, N. M. (2021) · medRxiv · doi:10.1101/2021.03.16.21253742 · Cited by 4
Guillain–Barre syndrome following COVID-19 vaccination: a study of 70 case reports
Sah, B. K., Fatima, Z., Sah, R. K., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001915 · Cited by 4
Analysis of the immune response in COVID-19
Hromić‐Jahjefendić, A., & Aljabali, A. A. A. (2025) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.10.004 · Cited by 4
Braverman, G., Barbhaiya, M., Nong, M., Bykerk, V. P., Hupert, N., Lewis, C., V, & Mandl, L. A. (2024) · Arthritis Care & Research · doi:10.1002/acr.25288 · Cited by 4
Strategies for Altering Delivery Technologies to Optimize CAR Therapy
Cao, L., Liu, Y., & Lin, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073206 · Cited by 6
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.